-+ 0.00%
-+ 0.00%
-+ 0.00%

AC Immune Announces Interim Safety And Efficacy Results From Phase 2 VacSYn Trial Of Its Wholly-Owned Anti-Alpha-Synuclein Active Immunotherapy ACI-7104.056 In Early Parkinson's Disease

Benzinga·12/11/2025 12:02:50
Listen to the news

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson's disease (PD).

The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD. Disease-related biomarker results, including a-syn CSF levels and neurofilament light (NfL), suggest stabilization of PD pathology. Plasma glial fibrillary acidic protein (GFAP) and dopamine transporter (DaT) SPECT imaging show trends toward disease modification. In addition, total scores on Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) are suggestive of a trend for stabilization.